Global Prader-Willi Syndrome Market Report 2019: $2110 Million Market Insights, Epidemiology and Forecasts 2018-2028
DUBLIN, Feb. 21, 2019 /PRNewswire/ --
The "Prader-Willi Syndrome - Market Insights, Epidemiology and Market Forecast-2028" report has been added to ResearchAndMarkets.com's offering.
The global market of Prader-Willi Syndrome (PWS) was estimated to be USD 2110.17 million in 2018
Prader-Willi Syndrome - Market Insights, Epidemiology and Market Forecast-2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Prader-Willi Syndrome in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Prader-Willi Syndrome (PWS) from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Prader-Willi Syndrome Epidemiology
According to this research, the prevalent population of Prader-Willi Syndrome was estimated to be 47,560 [7MM] in 2018. United States accounts for the highest Prader-Willi cases, followed by EU5 (Germany, France, Italy, Spain & UK) and Japan. Among the EU5 countries Germany had the highest prevalent patient population of Prader-Willi Syndrome, followed by Italy.
Prader-Willi Syndrome Drug Chapters
At present, pharmacological management of Prader-Willi Syndrome focuses largely on the use of human growth hormone (HGH) supplementation which is approved in the US. Growth hormone supplementation constitutes the primary component of the entire therapeutic market composition due to the nearly ubiquitous deficiency of growth hormone (GH) in PWS patients. Some of the majorly approved GH therapies include Pfizer's Genotropin (somatropin) along with other major brands such as Norditropin (Novo Nordisk) and a few others in the US. Central nervous system and cardiovascular agents are used with increasing frequency in older PWS patients. Another approved drug is Omnitrope (somatropin [rDNA origin] injection) from Sandoz. Detailed chapters for all of these drug therapies have been covered in the report.
Prader-Willi Syndrome Market Outlook
Amongst the therapeutic class, Hormone Therapies hold the highest patient share [%] amongst the other therapeutic options available for the treatment of PWS. The increasing awareness of the disease assisted by organizational support along with the promising pipeline therapies is expected to fuel the market size during the forecasted period of 2019-2028.
Prader-Willi Syndrome Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Upcoming therapies, such as DCCR (Soleno Therapeutics), LV-101 (Levo Therapeutics) and Lariglutide (Novo Nordisk), have the potential to create a positive shift in the PWS market size during the study period (2017-2028). Expected launch of potential therapies will lead to an increase in the market size of Prader-Willi Syndrome (PWS) in the coming years. DCCR (Soleno Therapeutics) is the going to be the first FDA approved therapy that is expected to be launched in all of the 7 Major Markets, during the forecast period [2018-2028].
Key Topics Covered:
1 Key Insights
2 Prader-Willi Syndrome Market Overview at a Glance
2.1 Market Share (%) Distribution of Prader-Willi Syndrome in 2017
2.2 Market Share (%) Distribution of Prader-Willi Syndrome in 2028
3 Prader-Willi syndrome: Disease Background and Overview
3.1 Introduction
3.2 Cause
3.3 Symptoms
3.4 Complications
3.5 Stages of Prader-Willi Syndrome
3.6 Molecular Genetic Pathogenesis
3.7 Diagnosis
4 Epidemiology and Patient Population
4.1 Key Findings
4.2 Population and Forecast Parameters
4.3 Total Prevalence of Prader-Willi Syndrome in 7MM
5 Country Wise-Epidemiology of Prader-Willi Syndrome
6 United States
6.1 Assumptions and Rationale
6.2 Prevalent Population of Prader-Willi Syndrome (PWS) in the United States
6.3 Diagnosed cases of PWS in the US
6.4 PWS cases by Mutation Types in the US
6.5 PWS associated Clinical Manifestations
7 EU-5
7.1 Assumptions and Rationale
8 Germany
8.1 Prevalent Population of Prader-Willi Syndrome (PWS) in Germany
8.2 Diagnosed cases of PWS in Germany
8.3 PWS cases by Mutation Types in Germany
8.4 PWS associated Clinical Manifestations
9 France
10 Italy
11 Spain
12 United Kingdom
13 Japan
14 Treatment
14.1.1 Consensus Guidelines for Recombinant Human Growth Hormone Therapy in Prader-Willi Syndrome
15 Unmet Needs
16 Marketed Drugs
16.1 GENOTROPIN: Pfizer
16.2 Other Hormonal Therapies
16.2.1 OMNITROPE: Sandoz Inc
16.3 Norditropin: Novo Nordisk
17 Emerging Drugs Analysis
18 Emerging Therapies
18.1 Diazoxide Choline Controlled-Release: Soleno Therapeutics
18.2 LV-101: Levo Therapeutics
18.3 Liraglutide: Novo Nordisk
18.3 Livoletide: Millendo Therapeutics
19 Prader-Willi Syndrome: 7 Major Market Analysis
19.1 Key Findings
19.2 Total Market Size of Prader-Willi Syndrome in 7MM
19.3 7 MM Size of Prader-Willi Syndrome by Therapies
20 Market Outlook by Country
20.1 The United States: Market Outlook
20.2 United States Market Size
20.3 EU-5 Countries: Market Outlook
20.4 Germany Market Size
20.5 France Market Size
20.6 Italy Market Size
20.7 Spain Market Size
20.8 The United Kingdom Market Size
20.9 Japan: Market Outlook
21 Market Drivers
22 Market Barriers
23 Appendix
Companies Mentioned
- Pfizer
- Sandoz Inc
- Novo Nordisk
- Soleno Therapeutics
- Levo Therapeutics
- Millendo Therapeutics
For more information about this report visit https://www.researchandmarkets.com/research/b8ndjz/global?w=5
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Media Contact:
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
Share this article